Latest Information Update: 01 Feb 2000
At a glance
- Originator Phytopharm
- Class Antipsoriatics
- Mechanism of Action Keratinocyte inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 01 Feb 2000 Discontinued-Preclinical for Psoriasis in United Kingdom (Topical)
- 19 Nov 1999 P 37 is available for licensing (http://www.phytopharm.co.uk)
- 15 Jan 1998 New profile